• Announced positive data from its CRO-67 drug candidate targeting pancreatic cancer, from a highly sophisticated study that tested the drug in a complex mouse model. • Released further preclinical data from the Chroma technology platform, showing two assets reduced tumour growth in a brain cancer explant model via a study conducted in conjunction with the University of South Australia. Significant changes in the state of affairs There were no significant changes in the state of affairs of the consolidated entity during the financial year. Matters subsequent to the end of the financial year During September 2025, the existing Convertible Note holders agreed to extend the maturity date of the convertible notes to 2 January 2027, on the same terms and conditions. Accrued interest will be paid to Noteholders for the period ending 2 January 2026 in cash. Interest will be accrued for the remaining life of the Notes. The Note holders will receive a total of 520,000 additional unlisted options for their ongoing financial support on the same terms as the original options issued to the Note holders (50,000 options for each $250,000 in Notes held, exercise price $0.1488, expiring 10 September 2027). In addition, during September 2025, 4F Investments Pty Limited (a company controlled by Fred Bart, Chairman) indicated its intention to subscribe to a secured Convertible Note for $1.25 million on the same terms and conditions as the $2.6 million in Notes issued to sophisticated investors in September 2024, subject to approval by shareholders at the upcoming AGM. In the interim 4F Investments has entered into a unsecured loan agreement with the Company whereby it will provide a $1.25M unsecured loan to the Company at 12% p.a. interest. Once shareholder approval has been obtained under sections 10.1 and 10.11 of the ASX Listing Rules, the unsecured loan facility will be rolled into a Convertible Note. Subsequent to shareholder approval being obtained for the issue of the Note to 4F Investments, 4F investments Pty Limited will receive as an incentive for participating in the Note 250,000 unlisted options (50,000 per $250,000 invested) at a strike price of $0.1488, with a three year term expiring on 10 September 2027 (on the same terms as issued to the existing Note holders). Except as noted above, no matter or circumstance has arisen since 30 June 2025 that has significantly affected, or may significantly affect the consolidated entity’s operations, the results of those operations, or the consolidated entity’s state of affairs in future financial years. Likely developments and expected results of operations Information on likely developments in the operations of the consolidated entity and the expected results of operations have not been included in this report because the directors believe it would be likely to result in unreasonable prejudice to the consolidated entity. Environmental regulation The consolidated entity is not subject to any significant environmental regulation under Australian Commonwealth or State law. Annual Report 2025 11
RkJQdWJsaXNoZXIy MjE2NDg3